X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dovitinib
Therapeutic Area: Oncology Product Name: TKI258
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Oncoheroes Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
Allarity’s focus on pediatric osteosarcoma development is based on the results of two previously reported preclinical studies in which treatment with dovitinib, compared to control treatment (sucrose solution lacking dovitinib).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dovitinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
The e-Poster provides new details of the Dovitinib-DRP® companion diagnostic, which is used to select cancer patients most likely to respond to the pan-targeted kinase inhibitor (pan-TKI) dovitinib.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
